INS and obesity due to melanocortin 4 receptor deficiency: These effects were expected given the previously reported studies that found the ability of RJ at doses of 100–300 mg/kg to reduce fasting glucose levels, modulate circulatory insulin levels, improve IR and HOMA-IR, lower HbA1C, and attenuate obesity in diabetic rats [25,27,32,37].